Meeting
2020 Genitourinary Cancers Symposium
Adenosine receptor blockade with ciforadenant +/- atezolizumab in advanced metastatic castration-resistant prostate cancer (mCRPC).
Authors
Lauren Christine Harshman
Dana-Farber Cancer Institute, Boston, MA
Lauren Christine Harshman , Michael Chu , Saby George , Brett Gordon Maxwell Hughes , Bradley Curtis Carthon , Lawrence Fong , Jaime R. Merchan , Long Kwei , Andrew N. Hotson , Mehrdad Mobasher , Richard A. Miller
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02655822
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 129)
Abstract #
129
Poster Bd #
F9
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase 1/2 open-label study of KY1044, an anti-ICOS antibody with dual mechanism of action, as single agent and in combination with atezolizumab, in adult patients with advanced malignancies.
First Author: Manish R. Patel
Poster
2020 ASCO Virtual Scientific Program
Results of a completed phase I study of LAM-002 (apilimod dimesylate), a first-in-class phosphatidylinositol-3-phosphate 5 kinase (PIKfyve) inhibitor, administered as monotherapy or with rituximab or atezolizumab to patients with previously treated follicular lymphoma or other B-cell cancers.
First Author: Catherine S. Magid Diefenbach
Poster
2019 ASCO Annual Meeting
An open label phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced solid/metastatic tumors.
First Author: Johann S. De Bono
Poster
2017 ASCO Annual Meeting
A first in human phase I study of AZD8186, a potent and selective inhibitor of PI3K in patients with advanced solid tumours as monotherapy and in combination with the dual mTORC1/2 inhibitor vistusertib (AZD2014) or abiraterone acetate.
First Author: Aaron Richard Hansen